Table 2. The loss of Brg1 and/or Brm can enhance cancer development via the up-regulation (as measured by qPCR) of 26 potential cancer-promoting genes from at least 5 categories (angiogenesis, anti-apoptosis, cancer progression, metastasis and proliferation).
| Gene Name | Aliases | Fold Change (Up) | Gene Function | Other Functions | ||
|---|---|---|---|---|---|---|
| Brm null | Brg1 KO | Doubles (DKO) | ||||
| Itga2 | CD49B, DX5 | 1.4 | 3.3 | 4.3 | Angiogenesis | Metastasis |
| Sema7A | Sema-L; semaphorin | 2.3 | 3.5 | 4.2 | Angiogenesis | Metastasis |
| Serpine1 | PAI-1 | 3.4 | 5.1 | 8.9 | Angiogenesis | Anti-apoptosis |
| Ear2 | Rnase2, Raf3 | 1.3 | 8.7 | 9.6 | Anti-apoptosis | |
| Hecw1 | Nedl1 | 2.2 | 4.4 | 5.1 | Anti-apoptosis | |
| Xaf1 | Fbox39 | 4.0 | 1.7 | 5.9 | Anti-apoptosis | |
| Ddx46 | PRPF5 | 9.5 | 3.5 | 10.2 | Cancer progression | |
| Epcam |
CD326, EGP, gp40 |
2.1 | 4.0 | 5.2 | Cancer progression | |
| Macc | Gm267 | 1.7 | 3.3 | 5.7 | Cancer progression | |
| Tmprss6 | IRIDA | 1.8 | 7.3 | 9.7 | Cancer progression | |
| Dkk1 | mdkk-1 | 1.1 | 5.4 | 7.4 | Metastasis | |
| Itga3 | CD49C, GAPB3 | 4.4 | 3.1 | 7.1 | Metastasis | |
| Pdpn | GP38, RANDAM-2 | Metastasis | ||||
| Plau | u-PA | 9.3 | 2.0 | 8.8 | Metastasis | Tamoxifen-Sensitive |
| SerpinB2 |
PAI-2, ovalbumin |
1.0 | 6.1 | 6.3 | Metastasis | |
| SerpinB5 | PI-5, Maspin | 1.1 | 3.2 | 3.5 | Metastasis | |
| Serpine1 | PAI-1 | 2.0 | 3.2 | 4.8 | Metastasis | |
| Etv1 |
ER81, Etsrp81 |
4.9 | 1.5 | 6.0 | Proliferation | Oncogene |
| Hapln1 | CLP, LP-1 | 0.7 | 1.8 | 5.3 | Proliferation | Oncogene |
| MycN | Nmyc-1 | 4.4 | 2.3 | 6.5 | Proliferation | Oncogene |
| Areg | Mcub, Sdgf | 4.1 | 1.6 | 4.5 | Proliferation | Oncogene |
| Grem1 | Drm | 3.0 | 1.7 | 4.6 | Proliferation | Oncogene |
| Ros1 | c-ros | 2.6 | 2.8 | 5.3 | Proliferation | Oncogene |
| Mcoln3 | TRPML3 | 2.2 | 2.3 | 4.4 | Proliferation | |
| Maf | -- | 2.0 | 6.0 | 8.1 | Proliferation | Oncogene |
| Muc1 | CD227, EMA | 1.4 | 3.0 | 3.9 | Proliferation | Metastasis |
The gene name and alias (when applicable) are given in columns 1 and 2, respectively. However, the fold induction of gene expression that was observed in BRM-null, BRG1-KO or DKO-derived tumors compared with wild type tumors is given in columns 3, 4 and 5, respectively. The potential gene function and/or other potential gene functions are listed in columns 6 and 7, respectively.